A new clue in Alzheimer’s could rewrite what we know about the disease
Industry Buzz
“It is a potential candidate for a common mechanism leading to the multisystem degeneration of the brain that precedes dementia.” — Bruce Yankner, MD, PhD, Professor of Genetics and neurology at Harvard Medical School
For decades, treatments for Alzheimer’s have focused on clearing amyloid beta plaques.[]
But a landmark study published in Nature on August 6, 2025,[]is sparking a new conversation: What if the absence—rather than the excess—of a naturally occurring metal in the brain is a key driver of Alzheimer’s?
Research led by Bruce Yankner, MD, PhD, Professor of Genetics and Neurology at Harvard Medical School, found that lithium, long known as a mood stabilizer, is actually present in the brain under normal physiological conditions.
Intriguingly, in Alzheimer’s and early cognitive impairment, lithium levels drop significantly—not just anywhere, but in regions burdened by amyloid plaques.[]
These plaques actively sequester lithium, robbing nearby brain tissue of its protective effects and creating a vicious cycle that accelerates neurodegeneration.
Related: Alzheimer’s starts in your 30s, says doc—here are 3 early blood markers that matterReversing the disease in mice
In mouse models, lithium deficiency led to hallmark Alzheimer’s changes, including increased inflammation of the brain’s immune cells and worse function of the surrounding neurons.[] Lithium-deficient mice and people with Alzheimer’s disease also shared similar gene expression profiles.
But here’s the twist: Giving lithium orotate—a lithium salt that resists sequestration by amyloid—to mice with signs of Alzheimer’s reversed these changes—and at just one-thousandth of the usual lithium dose, with no overt toxicity.[]
Beta amyloid plaques and tau tangles were reduced, and mice treated with the orotate were able to navigate mazes and learn how to identify new objects, while those administered a placebo showed no changes or improvements in their memory or thinking. This isn't just slowing cognitive decline—it’s reversing it.
“It is a potential candidate for a common mechanism leading to the multisystem degeneration of the brain that precedes dementia,” said Dr. Yankner.[]
Why this matters for clinicians
If these findings hold true in humans—and early clinical trials are on the horizon—this could shift Alzheimer’s treatment from managing damage to restoring function.
Unlike amyloid‑targeting antibodies, lithium appears to support the brain in multiple ways, helping to maintain synaptic integrity and form the myelin that coats the brain’s communication lines and aids microglial cells in clearing “cellular debris” that can impair the brain’s functioning.[]
It’s too early to prescribe lithium orotate to patients. “A mouse is not a human. Nobody should take anything based just on mouse studies ... The lithium treatment data we have is in mice, and it needs to be replicated in humans. We need to find the right dose in humans,” said Dr. Yankner.[]
But this study may lay the groundwork for two potential shifts in practice:
Screening for lithium deficiency: If future trials validate that low lithium levels precede symptoms, blood or CSF tests for lithium could become a novel early biomarker.
Clinical trials ahead: Lithium orotate or similar amyloid‑evading lithium compounds hold promise as disease‑modifying agents—not just plaque‑clearing but potentially symptom‑reversing. Physicians should watch for trial enrollment opportunities.